Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
Ana Oaknin, Claire F. Friedman, Lynda D. Roman, Anishka D'souza, Irene Braña, François‐Clément Bidard, Jonathan W. Goldman, Edwin Alvarez, Valentina Boni, Adam C. ElNaggar, Rodolfo Passalacqua, Khanh T.M., Alessandro D. Santin, Kiana Keyvanjah, Feng Xu, Lisa D. Eli, Alshad S. Lalani, Richard Bryce, David M. Hyman, Funda Meric‐Bernstam, David B. Solit, Bradley J. Monk
Topics & Concepts
MedicineNeratinibInternal medicineAdverse effectClinical endpointResponse Evaluation Criteria in Solid TumorsOncologyNauseaDiarrheaGastroenterologyCancerPhases of clinical researchSurgeryClinical trialBreast cancerTrastuzumabHER2/EGFR in Cancer ResearchEndometrial and Cervical Cancer TreatmentsAdvanced Breast Cancer Therapies